1 October 2019 in Arthroscopy
31 December 2019 in Arthroscopy
25 April 2020 in Microsurgery
13 May 2024 in Journal of Orthopaedic Reports
1 January 2021 in Foot & Ankle Orthopaedics
Background: High-pressure injections injuries to the extremities can result in significant disability, including amputation of the affected limb. Proprietary mixtures associated with drill mud and hydraulic fracking leads to frequent encounters with varied materials. The physician needs to be aware of the effect of these materials when inadvertent exposure occurs. Injected toxic materials cause extensive soft tissue inflammation and destruction. This puts the foot at risk not only to the cleaning fluid used, generally water, but any contaminant on the boot at the time of injury. This case report is the first known case report involving injection with drill mud contaminant and describes 2 oil field injuries resulting in the gross deep contamination of the foot from a high-pressure washer injury. Case Report: Two patients, a 46-year-old man (patient 1) and a 29-year-old man (patient 2) sustained high-pressure injection injuries to the foot. These patients underwent treatment with immediate broad-spectrum antibiotics and emergent irrigation and debridement on arrival to the treating facility. Neither patient underwent amputation of the affected extremity as a result of their injuries and achieved a full recovery and return to work. Conclusion: High-pressure injection injuries are operative emergencies. Treatment should include tetanus prophylaxis, neurovascular monitoring, broad-spectrum antibiotic coverage, emergent operative debridement for toxic materials. Despite the toxic nature of the injection injuries, aggressive treatment can improve the chance of salvage in these industrial injuries.
31 July 2026 in European Cells and Materials
Background: Biofilms shield bacteria from immune defenses and antibiotics, contributing to implant-associated infections, particularly those caused by Staphylococcus aureus (S. aureus). Halicin, a repurposed antimicrobial with broad-spectrum activity, has shown promise against planktonic and biofilm-residing bacteria. Building on our previous work, we investigated whether halicin enhances the efficacy of conventional antibiotics when used in combination against S. aureus. Methods: The treatment efficacies of combination therapies of Halicin and conventional antibiotics were tested against planktonic S. aureus and S. aureus biofilms grown on titanium substrates of varying maturities. The emergence of antibiotic resistance in treated biofilm bacteria was also characterized. Results: In checkerboard assays against planktonic bacteria, halicin synergized with gentamicin, tobramycin, and cefazolin but not with rifampicin or vancomycin. In biofilms grown on titanium substrates, halicin combined most effectively with rifampicin, reducing viable bacteria by >3 logs in less-mature and >5 logs in more-mature biofilms compared to rifampicin alone. Compared to untreated biofilms, combination therapy reduced viable bacteria by >5 logs in all cases. This combination also prevented rifampicin resistance seen with rifampicin monotherapy. Halicin only modestly enhanced aminoglycoside activity against less-mature biofilms and had no significant effect when combined with vancomycin or cefazolin. Conclusions: These findings highlight that antibiotic-halicin synergy differs between planktonic and biofilm states, underscoring the importance of biofilm-specific studies. Highlighting the translatability of our results, the doses of conventional antibiotics combined with halicin required to affect planktonic and biofilm-residing S. aureus are all achievable systemically and in bone.